
Immutep
IMM.AXImmutep Limited Price (IMM.AX)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
880,212,651
(3.6803)%Description
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small ce... Read More
Sector: Healthcare
- Previous Close Fetching Data...
- Range $0.23-0.485
- Market Cap 414.84M
- Enterprise Value No Data
- Avg Volume Fetching Data...
- P/E Ratio Fetching Data...
- Dividend Yield Fetching Data...
Industry: Biotechnology
- ceo: Mr. Marc Voigt
- IPO Date: June, 30, 1988
- Country: AU
- Currency: AUD
- Headquaters: Sydney, NSW
- Employees: 19
- Revenue from each product or segment:
Product or Segment | Value: | % - Total | Last 3Y: |
---|

- Revenue by Region
Product or Segment | Value: | % - Total | Last 3Y: |
---|
